Birch Pollen Allergy Clinical Trial
Official title:
A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06037148 -
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
|
Phase 1 | |
| Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
| Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
| Completed |
NCT01137357 -
Probiotics for Reduction Of Markers In Subjects With Allergy
|
N/A | |
| Active, not recruiting |
NCT05668390 -
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
|
Phase 3 | |
| Not yet recruiting |
NCT02146300 -
Effect of the Nasal Provocation on the Breathing Style
|
N/A | |
| Completed |
NCT01449786 -
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy
|
Phase 2 | |
| Completed |
NCT03969849 -
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
|
Phase 1 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT01628484 -
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
|
Phase 1 | |
| Completed |
NCT00932607 -
SUBLIVAC® Birch PROBE Study
|
Phase 2 | |
| Completed |
NCT02074930 -
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure
|
N/A | |
| Completed |
NCT02143583 -
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
|
Phase 2 | |
| Completed |
NCT04266028 -
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
|
Phase 1 | |
| Completed |
NCT00309062 -
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT01675791 -
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
|
Phase 2 |